Skip to main content

Table 1 Comparison of demographic and tumor characteristics based on the ABO blood group type

From: Effect of ABO blood group on postoperative overall survival and recurrence-free survival rate in patients with hepatocellular carcinoma after hepatectomy: a multi-center retrospective cohort study

Demographic characteristics

N: 641 patients with HCC

ABO blood group type

ABO blood group type

O

(N:219)

A

(N:201)

B

(N:148)

AB

(N:73)

P value

A

(N:201)

Non-A

(N:440)

P value

Age group

     

0.65

  

0.54

 • < 45 year

211 (32.9%)

69 (31.5%)

65 (32.3%)

54 (36.4%)

23 (29.5%)

 

65 (32.3%)

146 (33.2%)

 

 • 45–65 year

312 (48.7%)

107 (48.9%)

104 (51.7%)

74 (50%)

33 (42.3%)

 

104 (51.7%)

208 (47.3%)

 

 • > 65 year

118 (18.4%)

43 (19.6%)

32 (16%)

20 (13.6%)

22 (28.2%)

 

32 (16%)

86 (19.7%)

 

BMI (Kg/m2)

22.7 ± 2.89

22.9 ± 2.19

23.25 ± 3.11

21.54 ± 2.58

23.8 ± 2.55

0.44

23.25 ± 3.11

22.51 ± 3.09

0.41

Median survival (IQR 1, 3) Month)

32.5 (27.4, 37.6)

33.4 (28.5,38)

29.55 (24.7,34.3)

32.5 (28.1, 36.9)

32.8 (27.6, 37.8)

0.68

29.55 (24.7,34.3)

34.1 (29.4, 38.6)

0.54

Sex

     

0.88

  

0.75

 • Male

486 (75.8%)

162 (74%)

159 (79.1%)

109 (73.6%)

56 (76.7%)

 

159 (79.1%)

327 (74. 3%)

 

 • Female

155 (24.2%)

57 (26%)

42 (20.1%)

39 (26.4%)

22 (23.3%)

 

42 (20.1%)

113 (25.7%)

 

Smoking status

     

0.11

  

0.28

 • Yes

277 (43.2%)

99 (45.2%)

90 (44.8%)

60 (40.5%)

28 (38.4%)

 

90 (44.8%)

187 (42.5%)

 

 • NO

364 (56.8%)

120 (54.8%)

111 (55.2%)

88 (59.5%)

45 (61.6%)

 

111 (55.2%)

253 (57.5%)

 

Family history of GC

     

0.37

  

0.45

 • Yes

58 (9%)

21 (9.6%)

17 (8.5%)

11 (7.4%)

9 (12.3%)

 

17 (8.5%)

41 9.3%)

 

 • No

583 (91%)

198 (90.4%)

184 (91.5%)

137 (92.6%)

64 (87.7%)

 

184 (91.5%)

399 (90.7%)

 

Child–Pugh stage

     

0.22

  

0.28

 • A

512 (79.9%)

178 (81.3%)

153 (76.1%)

118 (79.7%)

63 (86.4%)

 

153 (76.1%)

359 (81.6%)

 

 • B

62 (9.7%)

25 (11.4%)

21 (10.5%)

11 (7.4%)

5 (6.8%)

 

21 (10.5%)

41 (9.3%)

 

 • Unknown & missing

67 (10.4%)

16 (7.3%)

27 (13.4%)

19 (12.9%)

5 (6.8%)

 

27 (13.4%)

40 (9.1%)

 

Tumor size (cm)

     

0.16

  

0.19

 • ≤ 5

317 (49.5%)

105 (47.9%)

93 (46.3%)

71 (48%)

43 (59%)

 

93 (46.3%)

224 (51%)

 

 • > 5

236 (36.8%)

82 (37.4%)

79 (39.3%)

50 (33.8%)

25 (34.2%)

 

79 (39.3%)

157 (35.7%)

 

 • Unknown & missing

88 (13.7%)

32 (14.7%)

29 (14.4%)

22 (18.2%)

5 (6.8%)

 

29 (14.4%)

59 (13.3%)

 

Metastasis

     

0.088

  

0.11

 • Yes

328 (51.2%)

104 (47.5%)

100 (49.8%)

79 (53.4%)

43 (58.9%)

 

100 (49.8%)

228 (51.8%)

 

 • No

110 (17.1%)

40 (18.2%)

36 (17.9%)

31 (20.9%)

5 (6.8%)

 

36 (17.9%)

74 16.8%)

 

 • Unknown & missing

203 (31.7%)

75 (34.3%)

65 (32.3%)

38 (25.7%)

25 (34.3%)

 

65 (32.3%)

138 (31.4%)

 

Involved Lymph node

     

0.12

  

0.087

 • < 2

325 (42.9%)

105 (48%)

86 (42.8%)

59 (39.9%)

25 (34.2%)

 

86 (42.8%)

239 (54.3%)

 

 • ≥ 2

166 (25.9%)

49 (22.3%)

54 (26.8%)

39 (26.3%)

24 (32.9%)

 

54 (26.8%)

112 (25.5%)

 

 • Unknown & missing

200 (31.2%)

65 (29.7%)

61 (30.4%)

50 (33.8%)

24 (32.9%)

 

61 (30.4%)

89 (20.2%)

 

Differentiation grade

     

0.054

  

0.049

 • Well

114 (17.8%)

40 (18.2%)

30 (14.9%)

34 (23%)

10 (13.7%)

 

30 (14.9%)

84 (19.1%)

 

 • Moderate

318 (49.6%)

110 (50.2%)

10 4 (51.7%)

69 (46.6%)

35 (47.9%)

 

104 (51.7%)

214 (48.6%)

 

 • Poor

128 (20%)

42 (19.2%)

50 (24.9%)

28 (18.9%)

8 (11%)

 

50 (24.9%)

78 (17.79%)

 

 • Unknown & missing

81 (12.6%)

27 (12.4%)

17 (8.5%)

17 (11.5%)

20 (27.4%)

 

17 (8.5%)

64 (14.6%)

 

Serum AFP level

     

0.095

  

0.068

 • < 400 ng/ml

338 (52.7%)

111 (50.7%)

99 (49.3%)

80 (54.1%)

43 (58.9%)

 

99 (49.3%)

239 (54.3%)

 

 • ≥ 400 ng/ml

205 (32%)

75 (34.2%)

68 (33.8%)

50 (33.8%)

12 (16.4%)

 

68 (33.8%)

137 (31.1%)

 

 • Unknown & missing

98 (15.3%)

33 (15.1%)

34 (16.9%)

13 (12.1%)

18 (24.7%)

 

34 (16.9%)

65 (14.6%)

 

Cirrhosis

     

0.11

  

0.098

 • Yes

258 (40.2%)

90 (41.1%)

85 (42.3%)

67 (45.3%)

16 (21.9%)

 

85 (42.3%)

173 9.3%)

 

 • No

135 (21.1%)

48 (21.9%)

42 (20.9%)

28 (18.9%)

17 (23.3%)

 

42 (20.9%)

93 (21.1%)

 

 • Unknown & missing

248 (38.7%)

81 (37%)

74 (36.8%)

53 (35.8%)

40 (54.8%)

 

74 (36.8%)

174 (39.6%)

 

Hepatitis type

     

0.084

  

0.14

 • None

135 (21.1%)

42 (19.2%)

42 (20.9%)

32 (21.6%)

19 (26.1%)

 

42 (20.9%)

93 (21.1%)

 

 • HBV

314 (49%)

96 (43.8%)

101 (50.2%)

76 (51.3%)

41 (56.2%)

 

101 (50.2%)

213 (48.4%)

 

 • HCV

119 (18.6%)

50 (22.8%)

38 (18.9%)

28 (18.9%)

3 (4.1%)

 

38 (18.9%)

81 (18.4%)

 

 • HBV + HCV

17 (2.7%)

5 (2.3%)

3 (1.5%)

2 (1.4%)

7 (9.5%)

 

3 (1.5%)

14 (3.2%)

 

 • Unknown & missing

56 (8.6%)

26 (11.9%)

17 (8.5%)

10 (6.8%)

3 (4.1%)

 

17 (8.5%)

39 (8.9%)

 

RH

     

0.58

  

0.66

 • + 

570 (88.9%)

197 (90%)

176 (87.6%)

132 (90.2%)

65 (89%)

 

176 (87.6%)

394 (89.5%)

 

 • -

71 (11.1%)

22 (10%)

25 (14.4%)

16 (10.8%)

8 (11%)

 

25 (14.4%)

46 (10.5%)

 
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us